Russian coronavirus vaccine Sputnik V will likely provide up to 2 years of immunity against Covid-19, compared to 4-5 months of immunity that could be achieved using a Covid vaccine developed by Pfizer and BioNTech. The Gamaleya research center, which is developing a vaccine against Sputnik V, made this claim on Monday.
A report in Wion quoted Alexander Gintsburg, the head of Russia’s Gamaleya research institute, as saying: “About our vaccine and the platform on which it was created, the Ebola vaccine, there is experimental evidence that using this platform, using similar preparatory methods, provides protection for at least two years, possibly longer. “
Further deepening the immunity expected to be obtained by using a Pfizer vaccine, Alexander Gintsburg said, “It is difficult to say how long the Pfizer vaccine will confer immunity, but based on the general findings of such vaccines, one should think that the period of protection will not more than four to five months, although that requires experimental data. “
Earlier this year Russia became the first country in the world to register a Covid-19 vaccine – Sputnik-V – named after Russia’s first satellite. It launched a massive vaccination program last week with developers saying the vaccine is 95% effective based on basic test results.
A press release from researchers at the Gamaleya Institute announced that the Russian experimental coronavirus vaccine Sputnik-V shows the effectiveness of 91.4 percent based on data analysis of the final checkpoint of clinical trials.
“The effectiveness of the Sputnik V vaccine is 91.4 percent, based on the final checkpoint analysis of data obtained 21 days after administration of the first dose,” the edition read.
According to Sputnik-V’s official website, the “advance to the third and final statistically significant representative checkpoint allowed the final demonstration of the vaccine’s effectiveness by more than 90 percent.”
RDIF CEO Kirill Dmitriev: “Today Gamaleya Institute and Russian Direct Investment Fund will announce the effective results of #SputnikV vaccine at the final checkpoint of clinical trials “- @rdif_press.
– Sputnik V (@sputnikvaccine) December 14, 2020
However, the center’s deputy director of science, Denis Logunov, said the institute expects the effectiveness of its vaccine to further increase.
Despite the start of the Russian vaccination campaign, Sputnik V has not yet completed its third and final phase of testing with about 40,000 volunteers.
Meanwhile, the coronavirus vaccine developed by Pfizer showed 95 percent effectiveness in the late phase, the company said earlier.
In a major development, the United States is now the sixth country to approve the two-dose regime, after Britain, Bahrain, Canada, Saudi Arabia and Mexico.
After the UK, the US and Canada became the two other nations in the world to start vaccine drives against Covid-19 with the Pfizer-BioNtech vaccine dose. Both the United States and Canada have begun administering the Pfizer vaccine dose against coronavirus to health care workers and elderly citizens.
(With AFP inputs)